2021 American Transplant Congress
Hospitalization in the First Year After Kidney Transplantation: Analyses to Identify Common Predictors of Risk Across Recipient Sensitization Groups
University of Florida, Gainesville, FL
*Purpose: We investigated the risk of hospitalization associated with baseline risk factors in adult deceased donor (DD) kidney transplant (KT) recipients (KTRs) stratified into calculated…2021 American Transplant Congress
Evaluation of the Conversion from Tacrolimus to Sirolimus in Liver Transplant Recipients
1Mercer University College of Pharmacy, Atlanta, GA, 2Emory University Hospital, Atlanta, GA
*Purpose: The purpose of this study was to compare outcomes in liver transplant patients maintained on standard calcineurin inhibitor (CNI) therapy with tacrolimus versus those…2021 American Transplant Congress
Kidney Transplant Outcomes Stratified by Race with a Calcineurin and Steroid Free Regimen
Pharmacy, Duke University Medical Center, Durham, NC
*Purpose: This study aimed to describe the outcomes, stratified by race, associated with belatacept and sirolimus immunosuppression after alemtuzumab induction.*Methods: This was a retrospective, single-center…2021 American Transplant Congress
COVID-19 in Hospitalized Kidney Transplant Recipients: Clinical Course, Prognostic Factors and Differences Between First and Second Waves
Nephrology, Hospital Gregorio Marañón, Madrid, Spain
*Purpose: The aim was to describe the clinical course and management of SARS-CoV-2 infection in kidney transplant recipients (KTR) hospitalized with COVID-19, identify risk factors…2021 American Transplant Congress
Associations of Mammalian Target of Rapamycin Inhibitors with Post-Transplant Malignancies and All-Cause Mortality: Cause-Specific Competing Risks and Composite Outcomes Analyses
1University of Florida, Gainesville, FL, 2University of Rhode Island, Kingston, RI
*Purpose: We investigated the outcomes of malignancies and mortality associated with mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs).*Methods:…2020 American Transplant Congress
Conversion to Sirolimus to Prevent Recurrent Cytomegalovirus Infection/Disease: A Prospective and Randomized Trial
Hospital do Rim - UNIFESP, São Paulo, Brazil
*Purpose: Recurrent cytomegalovirus (CMV) infection occurs in 30-35% of kidney transplant recipients after completion of treatment and/or preemptive therapy. There is no consensus on the…2020 American Transplant Congress
Immuno-Modulation of Primed Xenogeneic T Cell Response by mTOR Blockade of T Cells and Porcine Endothelial Cells
Surgery, Duke University, Durham, NC
*Purpose: Porcine vascular endothelial cells (PECs) play a central role in xeno-recognition and costimulation. The objectives of this study were to characterize the immuno-phenotype of…2020 American Transplant Congress
Sirolimus Combined with Low-Dose Calcineurin Inhibitor in Kidney Transplant Recipients from Expanded Criteria Donors
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: To evaluate the efficacy and safety of conversion from calcineurin inhibitor-based immunosuppressive regimen to sirolimus combined with low-dose calcineurin inhibitor in recipients with abnormal…2020 American Transplant Congress
The Impact of Sirolimus on Weight Gain Post Heart Transplant
*Purpose: Obesity is common after heart transplant (HT), resulting in increased risk of new onset diabetes, all-cause and cardiovascular mortality and graft failure. Immunosuppressants (ISN)…2020 American Transplant Congress
Long Term Effect of Tacrolimus Conversion to Sirolimus with Prednisone-Free Regimen in Kidney Allograft Outcomes: A Dynamic Analysis of Graft Survival Using Joint Modeling
*Purpose: Findings on long-term impacts of the mammalian target of rapamycin inhibitor inhibitors on kidney allograft are scarce and mixed. A joint modeling approach can…
- 1
- 2
- 3
- …
- 5
- Next Page »